AR048652A1 - 4-fenilamino-quinazolin-6-il-amidas - Google Patents
4-fenilamino-quinazolin-6-il-amidasInfo
- Publication number
- AR048652A1 AR048652A1 ARP050101797A ARP050101797A AR048652A1 AR 048652 A1 AR048652 A1 AR 048652A1 AR P050101797 A ARP050101797 A AR P050101797A AR P050101797 A ARP050101797 A AR P050101797A AR 048652 A1 AR048652 A1 AR 048652A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- piperazine
- quinazolin
- het
- pyrrolidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente trata de 4-fenilamino-quinazolin-6-il-amidas, así como procedimientos y los compuestos intermedios para prepararlos, composiciones farmacéuticas utiles y procedimientos para usar los compuestos en el tratamiento de enfermedades proliferativas. Reivindicacion 1: Un compuesto de la formula (1) en la que: R1 se selecciona de F, Br, Cl o I; R2 se selecciona de H, F, Br, Cl o I; R3 se selecciona de: a) alquilo C1-3 lineal o ramificado, opcionalmente sustituido con uno o más halogenos; o b) -(CH2)n-morfolino, -(CH2)n-piperidina, -(CH2)n-piperazina, -(CH2)n-piperazina-N-(alquilo C1-3), -(CH2)n-pirrolidina o -(CH2)n-imidazol; n es un numero entero de 1 a 4; R4 es -(CH2)m-Het; Het es un resto heterocíclico seleccionado del grupo de morfolina, piperidina, piperazina, piperazina-N-(alquilo C1-3), imidazol, pirrolidina, azepan, 3,4-dihidro-2H-piridina o 3,6-dihidro-2H-piridina, donde cada resto heterocíclico está opcionalmente sustituido con de 1 a 3 grupos seleccionados de alquilo C1-3, halogeno, OH, NH2, NH-alquilo C1-3 o N-(alquilo C1-3)2; m es un numero entero de 1 a 3; y X es O, S o NH; o una sal farmacéuticamente aceptable del mismo
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56887204P | 2004-05-06 | 2004-05-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR048652A1 true AR048652A1 (es) | 2006-05-10 |
Family
ID=34965519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050101797A AR048652A1 (es) | 2004-05-06 | 2005-05-04 | 4-fenilamino-quinazolin-6-il-amidas |
Country Status (48)
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1746999T3 (da) | 2004-05-06 | 2012-01-23 | Warner Lambert Co | 4-phenylamino-quinazolin-6-yl-amider |
| KR100735639B1 (ko) | 2004-12-29 | 2007-07-04 | 한미약품 주식회사 | 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법 |
| KR100929146B1 (ko) | 2006-06-28 | 2009-12-01 | 한미약품 주식회사 | 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 |
| US9073916B2 (en) | 2009-03-11 | 2015-07-07 | Auckland Uniservices Limited | Prodrug forms of kinase inhibitors and their use in therapy |
| CN102146059A (zh) * | 2010-02-08 | 2011-08-10 | 上海艾力斯医药科技有限公司 | 喹唑啉衍生物、制备方法及其应用 |
| CN102382106A (zh) | 2010-08-30 | 2012-03-21 | 黄振华 | 苯胺取代的喹唑啉衍生物 |
| CN102382065B (zh) * | 2010-08-30 | 2014-05-28 | 山东轩竹医药科技有限公司 | 苯胺取代的喹唑啉衍生物 |
| CN102452989B (zh) * | 2010-10-19 | 2014-10-22 | 山东轩竹医药科技有限公司 | 苯胺取代的喹唑啉衍生物 |
| US8828391B2 (en) | 2011-05-17 | 2014-09-09 | Boehringer Ingelheim International Gmbh | Method for EGFR directed combination treatment of non-small cell lung cancer |
| HUE033575T2 (hu) | 2011-05-26 | 2017-12-28 | Xuanzhu Pharma Co Ltd | Tirozin-kináz inhibitor kinazolin származék, elõállítási eljárása és alkalmazása |
| CN102838590B (zh) * | 2011-06-21 | 2014-07-09 | 苏州迈泰生物技术有限公司 | 氨基喹唑啉衍生物及其在制备抗恶性肿瘤药物中的用途 |
| KR20140093223A (ko) * | 2011-10-12 | 2014-07-25 | 텔리진 엘티디. | 키나제 억제제로서의 퀴나졸린 유도체 및 이의 사용 방법 |
| TWI532727B (zh) | 2012-01-17 | 2016-05-11 | 安斯泰來製藥股份有限公司 | 吡羧醯胺化合物 |
| WO2013166952A1 (en) | 2012-05-07 | 2013-11-14 | Teligene Ltd | Substituted aminoquinazolines useful as kinases inhibitors |
| WO2014177038A1 (en) | 2013-04-28 | 2014-11-06 | Sunshine Lake Pharma Co., Ltd. | Aminoquinazoline derivatives and their salts and methods of use thereof |
| CN103288758B (zh) * | 2013-05-16 | 2015-01-21 | 苏州明锐医药科技有限公司 | 一种达克米替尼的制备方法 |
| CN103288759B (zh) * | 2013-05-16 | 2015-05-20 | 苏州明锐医药科技有限公司 | 达克米替尼的制备方法 |
| WO2014187319A1 (en) | 2013-05-21 | 2014-11-27 | Jiangsu Medolution Ltd | Substituted pyrazolopyrimidines as kinases inhibitors |
| CN103304492B (zh) * | 2013-06-20 | 2015-12-23 | 湖南欧亚生物有限公司 | 一种EGFR抑制剂Dacomitinib的合成方法 |
| CN105705494B (zh) * | 2013-07-18 | 2017-12-15 | 锦州奥鸿药业有限责任公司 | 喹唑啉衍生物及其药物组合物，以及作为药物的用途 |
| CN105859641B (zh) * | 2015-05-05 | 2018-11-16 | 杭州华东医药集团新药研究院有限公司 | 喹唑啉巴豆基化合物二马来酸盐的晶体及其制备方法和用途 |
| AU2017204973A1 (en) * | 2016-01-06 | 2018-07-12 | Trillium Therapeutics Inc. | Novel fluorinated quinazoline derivatives as EGFR inhibitors |
| CN107721985A (zh) * | 2016-08-12 | 2018-02-23 | 山东轩竹医药科技有限公司 | 喹唑啉类酪氨酸激酶抑制剂的晶型 |
| CN107721986A (zh) * | 2016-08-12 | 2018-02-23 | 山东轩竹医药科技有限公司 | 喹唑啉类酪氨酸激酶抑制剂的晶型 |
| CN107721987A (zh) * | 2016-08-12 | 2018-02-23 | 山东轩竹医药科技有限公司 | 喹唑啉类酪氨酸激酶抑制剂的晶型 |
| CN107793368B (zh) * | 2016-08-31 | 2021-10-15 | 四川科伦药物研究院有限公司 | 达可替尼溶剂化物、其新晶型及其制备方法和用途 |
| KR102213040B1 (ko) * | 2017-12-20 | 2021-02-05 | 한국원자력의학원 | 방사선 손상 보호 또는 완화, 및 폐섬유화 예방 또는 치료 용도 |
| CN109438423A (zh) * | 2018-09-12 | 2019-03-08 | 通化师范学院 | 一种肺癌靶向化合物azd-3759的合成工艺的新方法 |
| BR112021005513A2 (pt) | 2018-09-25 | 2021-06-22 | Black Diamond Therapeutics, Inc. | derivados de quinazolina como inibidor de tirosina quinase, composições, métodos de fabricação e uso dos mesmos |
| EP3903828A4 (en) | 2018-12-21 | 2022-10-05 | Daiichi Sankyo Company, Limited | COMBINATION OF AN ANTIBODY-DRUG CONJUGATE AND A KINASE INHIBITOR |
| MX2021011810A (es) | 2019-03-29 | 2021-10-26 | Astrazeneca Ab | Osimertinib para su uso en el tratamiento de cancer de pulmon de celulas no peque?as. |
| WO2021094379A1 (en) | 2019-11-12 | 2021-05-20 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| CN113045541A (zh) * | 2019-12-27 | 2021-06-29 | 广东东阳光药业有限公司 | Egfr抑制剂新晶型及其制备方法 |
| AU2021211871A1 (en) | 2020-01-20 | 2022-09-08 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| CN113717111A (zh) * | 2020-05-25 | 2021-11-30 | 苏州晶云药物科技股份有限公司 | 喹唑啉类化合物的晶型及其制备方法 |
| US20210369709A1 (en) | 2020-05-27 | 2021-12-02 | Astrazeneca Ab | EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER |
| US11858925B2 (en) | 2020-07-10 | 2024-01-02 | The Regents Of The University Of Michigan | GAS41 inhibitors and methods of use thereof |
| CN112707869B (zh) * | 2020-12-25 | 2022-03-22 | 扬子江药业集团有限公司 | 一种达可替尼杂质及其制备方法 |
| IL315848A (en) | 2022-03-31 | 2024-11-01 | Astrazeneca Ab | Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in combination with an AKT inhibitor for cancer treatment |
| WO2023209086A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds for treating cancer |
| WO2023209084A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer |
| WO2023209088A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their use in the treatment of cancer |
| WO2023209090A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their application in the treatment of cancer |
| WO2024002938A1 (en) | 2022-06-27 | 2024-01-04 | Astrazeneca Ab | Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
Family Cites Families (109)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1340821C (en) | 1988-10-06 | 1999-11-16 | Nobuyuki Fukazawa | Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components |
| MX22406A (es) | 1989-09-15 | 1994-01-31 | Pfizer | Nuevos derivados de n-aril y n-heteroarilamidas y urea como inhibidores de acil coenzima a: acil transferasa del colesterol (acat). |
| US5362878A (en) * | 1991-03-21 | 1994-11-08 | Pfizer Inc. | Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT) |
| CZ281628B6 (cs) * | 1991-07-29 | 1996-11-13 | Warner-Lambert Company | Deriváty chinazolinu a farmaceutické přípravky na jejich bázi |
| CZ281314B6 (cs) | 1991-08-22 | 1996-08-14 | Warner-Lambert Company | Amidtetrazoly inhibující cholesterolacyltransferasu |
| US5366987A (en) * | 1991-08-22 | 1994-11-22 | Warner-Lambert Company | Isoxazolyl-substituted alkyl amide ACAT inhibitors |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| US5412714A (en) * | 1992-02-24 | 1995-05-02 | At&T Corp. | Mnemonic and synonymic addressing in a telecommunications system |
| GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
| PH31122A (en) * | 1993-03-31 | 1998-02-23 | Eisai Co Ltd | Nitrogen-containing fused-heterocycle compounds. |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| WO1995023141A1 (en) * | 1994-02-23 | 1995-08-31 | Pfizer Inc. | 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents |
| GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| TW321649B (es) * | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
| GB9424233D0 (en) | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
| GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| DE69613367T2 (de) * | 1995-04-27 | 2002-04-18 | Astrazeneca Ab, Soedertaelje | Chinazolin derivate |
| GB9508565D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| GB9508537D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| EP0876345B1 (en) * | 1995-10-16 | 2004-08-18 | Fujisawa Pharmaceutical Co., Ltd. | Heterocyclic compounds as h+-atpases |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| US5760041A (en) * | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| ES2194181T3 (es) * | 1996-02-13 | 2003-11-16 | Astrazeneca Ab | Derivados de quinazolina como inhibidores de vegf. |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| GB9603097D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline compounds |
| CA2244897C (en) * | 1996-03-05 | 2006-04-11 | Zeneca Limited | 4-anilinoquinazoline derivatives |
| BR9708640B1 (pt) * | 1996-04-12 | 2013-06-11 | inibidores irreversÍveis de tirosina-cinases e composiÇço farmacÊutica compreendendo os mesmo. | |
| GB9607729D0 (en) | 1996-04-13 | 1996-06-19 | Zeneca Ltd | Quinazoline derivatives |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| DE69716916T2 (de) | 1996-07-13 | 2003-07-03 | Glaxo Group Ltd., Greenford | Kondensierte heterozyklische verbindungen als protein kinase inhibitoren |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| US6225318B1 (en) * | 1996-10-17 | 2001-05-01 | Pfizer Inc | 4-aminoquinazolone derivatives |
| JP4713698B2 (ja) | 1997-03-05 | 2011-06-29 | スージェン， インク． | 疎水性薬剤の処方 |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| AR012634A1 (es) | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
| CN1195521C (zh) | 1997-05-06 | 2005-04-06 | 惠氏控股公司 | 喹唑啉化合物在治疗多囊肾病中的应用 |
| US5929080A (en) | 1997-05-06 | 1999-07-27 | American Cyanamid Company | Method of treating polycystic kidney disease |
| ZA986729B (en) * | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| ZA986732B (en) * | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| US6251912B1 (en) | 1997-08-01 | 2001-06-26 | American Cyanamid Company | Substituted quinazoline derivatives |
| WO1999024037A1 (en) | 1997-11-06 | 1999-05-20 | American Cyanamid Company | Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps |
| US6323209B1 (en) | 1997-11-06 | 2001-11-27 | American Cyanamid Company | Method of treating or inhibiting colonic polyps |
| GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| EP1082311A1 (en) | 1998-05-28 | 2001-03-14 | Parker Hughes Institute | Quinazolines for treating brain tumor |
| US6384223B1 (en) * | 1998-07-30 | 2002-05-07 | American Home Products Corporation | Substituted quinazoline derivatives |
| EP1100788B1 (en) | 1998-07-30 | 2005-11-09 | Wyeth | Substituted quinazoline derivatives |
| BRPI9914164B8 (pt) | 1998-09-29 | 2021-05-25 | American Cyanamid Co | compostos de 3-ciano quinolina |
| US6297258B1 (en) * | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| GEP20032997B (en) * | 1998-11-19 | 2003-06-25 | Warner Lambert Co | N-[4-(3-Chloro-4-Fluoro-Phenylamino)-7-(3-Morpholin-4-Yl-Propoxy)-Quinazolin-6-Yl]-crylamide, as an Irreversible Inhibitor of Tyrosine Kinases |
| NZ513802A (en) | 1999-02-27 | 2001-09-28 | Boehringer Ingelheim Pharma | 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases |
| DE19911509A1 (de) | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| YU13200A (sh) * | 1999-03-31 | 2002-10-18 | Pfizer Products Inc. | Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja |
| MXPA01012899A (es) * | 1999-06-21 | 2002-07-30 | Boehringer Ingelheim Pharma | Heterociclos biciclicos, medicamentos que contienen estos compuestos, su empleo y procedimientos para su preparacion. |
| AUPQ113799A0 (en) * | 1999-06-22 | 1999-07-15 | University Of Queensland, The | A method and device for measuring lymphoedema |
| NZ517120A (en) | 1999-08-12 | 2004-10-29 | Wyeth Corp | NSAID and EFGR kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer |
| IL148489A0 (en) | 1999-09-21 | 2002-09-12 | Astrazeneca Ab | Quinazoline compounds and pharmaceutical compositions containing them |
| US6664390B2 (en) * | 2000-02-02 | 2003-12-16 | Warner-Lambert Company Llc | Method for the simplified production of (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-nitro-quinazoline-4-yl]-amine or (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-amino-quinazoline-4-yl]-amine |
| US6384051B1 (en) * | 2000-03-13 | 2002-05-07 | American Cyanamid Company | Method of treating or inhibiting colonic polyps |
| BR0109828A (pt) | 2000-04-07 | 2002-12-17 | Astrazeneca Ab | Composto, processo para a prepapação do mesmo ou de um sal deste, composição farmacêutica, uso do composto ou de um sal deste farmaceuticamente aceitável, e, método para a produção de um efeito antiangiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente em necessidade de tal tratamento |
| US6627634B2 (en) * | 2000-04-08 | 2003-09-30 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them |
| EP1280798B1 (de) * | 2000-04-08 | 2007-01-03 | Boehringer Ingelheim Pharma GmbH & Co.KG | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| DE10031971A1 (de) * | 2000-06-30 | 2002-01-10 | Goedecke Ag | Polymorphe Formen/Hydrate von N-[4-(3-Chlor-4-fluor-phenylamino)-7-(3-morpholin-4-yl-propoxy)-chinazolin-6-yl]-acrylamid Dihydrochlorid, Verfahren zu ihrer Herstellung sowie die Verwendung derselben zur Herstellung von Medikamenten mit irreversibler Tyrosinkinasehemmwirkung |
| US6446671B2 (en) * | 2000-08-04 | 2002-09-10 | John G. Armenia | Double wall safety hose |
| US6740651B2 (en) * | 2000-08-26 | 2004-05-25 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
| US6403580B1 (en) * | 2000-08-26 | 2002-06-11 | Boehringer Ingelheim Pharma Kg | Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| US6617329B2 (en) * | 2000-08-26 | 2003-09-09 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines and their use as medicaments |
| US20020082270A1 (en) * | 2000-08-26 | 2002-06-27 | Frank Himmelsbach | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
| US6653305B2 (en) * | 2000-08-26 | 2003-11-25 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them |
| US6656946B2 (en) * | 2000-08-26 | 2003-12-02 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
| RU2264389C3 (ru) * | 2000-10-20 | 2018-06-01 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Азотсодержащие ароматические производные, их применение, лекарственное средство на их основе и способ лечения |
| US20030158196A1 (en) * | 2002-02-16 | 2003-08-21 | Boehringer Ingelheim Pharma Gmbh Co. Kg | Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors |
| DE10063435A1 (de) * | 2000-12-20 | 2002-07-04 | Boehringer Ingelheim Pharma | Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| US7019012B2 (en) * | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
| PA8539401A1 (es) * | 2001-02-14 | 2002-10-28 | Warner Lambert Co | Quinazolinas como inhibidores de mmp-13 |
| DE60237145D1 (de) | 2001-02-21 | 2010-09-09 | Mitsubishi Tanabe Pharma Corp | Chinazolinderivate |
| WO2002092578A1 (en) | 2001-05-14 | 2002-11-21 | Astrazeneca Ab | Quinazoline derivatives |
| WO2002092577A1 (en) | 2001-05-14 | 2002-11-21 | Astrazeneca Ab | Quinazoline derivatives |
| GB0118752D0 (en) * | 2001-08-01 | 2001-09-26 | Pfizer Ltd | Process for the production of quinazolines |
| CA2465068A1 (en) | 2001-11-03 | 2003-05-15 | Astrazeneca Ab | Quinazoline derivatives as antitumor agents |
| GB0126433D0 (en) | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
| GB0128108D0 (en) | 2001-11-23 | 2002-01-16 | Astrazeneca Ab | Therapeutic use |
| DE60223279T2 (de) * | 2001-11-30 | 2008-05-29 | Osi Pharmaceuticals, Inc. | Verfahren für die herstellung substituierter bicyclischer derivate zur behandlung von anomalem zellwachstum |
| PL373848A1 (en) * | 2001-12-12 | 2005-09-19 | Pfizer Products Inc. | Quinazoline derivatives for the treatment of abnormal cell growth |
| CN100491372C (zh) | 2001-12-24 | 2009-05-27 | 阿斯特拉曾尼卡有限公司 | 作为欧若拉激酶抑制剂的取代喹唑啉衍生物 |
| DE10204462A1 (de) | 2002-02-05 | 2003-08-07 | Boehringer Ingelheim Pharma | Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse |
| MXPA04008307A (es) | 2002-02-26 | 2004-11-26 | Astrazeneca Ab | Formulacion farmaceutica de iressa que comprende un derivado de celulosa soluble en agua. |
| US7645878B2 (en) | 2002-03-22 | 2010-01-12 | Bayer Healthcare Llc | Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof |
| TW200813014A (en) | 2002-03-28 | 2008-03-16 | Astrazeneca Ab | Quinazoline derivatives |
| US20040044014A1 (en) | 2002-04-19 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof |
| DE10217689A1 (de) * | 2002-04-19 | 2003-11-13 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung |
| US20030225079A1 (en) | 2002-05-11 | 2003-12-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy |
| DE10221018A1 (de) * | 2002-05-11 | 2003-11-27 | Boehringer Ingelheim Pharma | Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie |
| US20040048887A1 (en) * | 2002-07-09 | 2004-03-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors |
| PA8578001A1 (es) | 2002-08-07 | 2004-05-07 | Warner Lambert Co | Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas |
| KR20050122199A (ko) | 2003-01-23 | 2005-12-28 | 티.케이. 시그널 리미티드 | 표피성장인자 수용체 티로신 키나제의 비가역성 억제제 및 그의 용도 |
| PE20040945A1 (es) * | 2003-02-05 | 2004-12-14 | Warner Lambert Co | Preparacion de quinazolinas substituidas |
| US7223749B2 (en) * | 2003-02-20 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| KR20050118726A (ko) * | 2003-04-09 | 2005-12-19 | 화이자 프로덕츠 인코포레이티드 | Ｎ-((((피리딘일옥시)-페닐아미노)퀴나졸리닐)-알릴)아세트아마이드 유도체와 이와 관련된 화합물의 제조방법, 이제조방법의 중간체, 및 이 중간체의 제조방법 |
| BRPI0409427A (pt) | 2003-04-16 | 2006-04-18 | Astrazeneca Ab | composto, uso do mesmo, composição farmacêutica, método de tratamento de um humano sofrendo de uma doença hiperproliferativa, e, processo para a preparação de um composto ou de um sal, éster ou pró-droga farmaceuticamente aceitáveis do mesmo |
| CA2536140A1 (en) | 2003-08-18 | 2005-02-24 | Pfizer Products Inc. | Dosing schedule for erbb2 anticancer agents |
| EP1673346A1 (en) | 2003-10-06 | 2006-06-28 | GPC Biotech AG | Quinazoline derivatives for the treatment of herpesviral infections |
| JPWO2005051924A1 (ja) * | 2003-11-28 | 2007-06-21 | 三菱ウェルファーマ株式会社 | キナゾリン誘導体及びその製造方法 |
| DK1746999T3 (da) * | 2004-05-06 | 2012-01-23 | Warner Lambert Co | 4-phenylamino-quinazolin-6-yl-amider |
-
2005
- 2005-04-25 DK DK05732761.1T patent/DK1746999T3/da active
- 2005-04-25 RS RS20120004A patent/RS52119B/en unknown
- 2005-04-25 EP EP05732761A patent/EP1746999B1/en active Active
- 2005-04-25 KR KR1020087022983A patent/KR20080095915A/ko not_active Application Discontinuation
- 2005-04-25 BR BRPI0510604A patent/BRPI0510604B8/pt active IP Right Grant
- 2005-04-25 MX MXPA06012756A patent/MXPA06012756A/es active IP Right Grant
- 2005-04-25 PL PL05732761T patent/PL1746999T3/pl unknown
- 2005-04-25 PT PT05732761T patent/PT1746999E/pt unknown
- 2005-04-25 CA CA2565812A patent/CA2565812C/en active Active
- 2005-04-25 AP AP2006003810A patent/AP2204A/xx active
- 2005-04-25 ME MEP-2012-2A patent/ME01267B/me unknown
- 2005-04-25 UA UAA200611675A patent/UA85706C2/ru unknown
- 2005-04-25 ES ES05732761T patent/ES2374553T3/es active Active
- 2005-04-25 KR KR1020067023121A patent/KR100885835B1/ko active IP Right Grant
- 2005-04-25 JP JP2007512544A patent/JP4205757B2/ja active Active
- 2005-04-25 CN CN2005800145175A patent/CN1972688B/zh active Active
- 2005-04-25 GE GEAP20059692A patent/GEP20084551B/en unknown
- 2005-04-25 WO PCT/IB2005/001139 patent/WO2005107758A1/en active Application Filing
- 2005-04-25 SI SI200531429T patent/SI1746999T1/sl unknown
- 2005-04-25 AT AT05732761T patent/ATE533490T1/de active
- 2005-04-25 AU AU2005239878A patent/AU2005239878B9/en active Active
- 2005-04-25 NZ NZ550796A patent/NZ550796A/en unknown
- 2005-04-25 EA EA200601849A patent/EA011237B1/ru active Protection Beyond IP Right Term
- 2005-04-29 MY MYPI20051908A patent/MY143566A/en unknown
- 2005-05-03 PE PE2005000494A patent/PE20060215A1/es active IP Right Grant
- 2005-05-03 TW TW094114254A patent/TWI334865B/zh active
- 2005-05-04 NL NL1028967A patent/NL1028967C2/nl active Search and Examination
- 2005-05-04 PA PA20058631901A patent/PA8631901A1/es unknown
- 2005-05-04 GT GT200500103A patent/GT200500103A/es unknown
- 2005-05-04 HN HN2005000192A patent/HN2005000192A/es unknown
- 2005-05-04 AR ARP050101797A patent/AR048652A1/es active IP Right Grant
- 2005-05-05 UY UY28885A patent/UY28885A1/es active IP Right Grant
- 2005-05-05 US US11/122,345 patent/US7772243B2/en active Active
-
2006
- 2006-10-23 IL IL178822A patent/IL178822A/en active IP Right Grant
- 2006-10-30 ZA ZA200609012A patent/ZA200609012B/xx unknown
- 2006-11-02 NI NI200600262A patent/NI200600262A/es unknown
- 2006-11-03 CR CR8727A patent/CR8727A/es unknown
- 2006-11-03 MA MA29435A patent/MA28632B1/fr unknown
- 2006-11-03 TN TNP2006000360A patent/TNSN06360A1/fr unknown
- 2006-11-08 EC EC2006006976A patent/ECSP066976A/es unknown
- 2006-12-06 NO NO20065626A patent/NO339692B1/no active Protection Beyond IP Right Term
-
2007
- 2007-10-29 HK HK07111642.2A patent/HK1106432A1/xx unknown
-
2008
- 2008-07-11 JP JP2008180894A patent/JP4966923B2/ja active Active
-
2010
- 2010-04-05 US US12/754,556 patent/US8466165B2/en active Active
-
2011
- 2011-12-02 CY CY20111101196T patent/CY1112127T1/el unknown
- 2011-12-20 HR HR20110958T patent/HRP20110958T1/hr unknown
-
2013
- 2013-06-10 US US13/914,410 patent/US8623883B2/en active Active
-
2019
- 2019-08-29 CY CY2019034C patent/CY2019034I1/el unknown
- 2019-09-10 LT LTPA2019016C patent/LTC1746999I2/lt unknown
- 2019-09-11 HU HUS1900039C patent/HUS1900039I1/hu unknown
- 2019-09-12 LU LU00127C patent/LUC00127I2/fr unknown
- 2019-09-12 BE BE2019C540C patent/BE2019C540I2/nl unknown
- 2019-09-12 FR FR19C1052C patent/FR19C1052I2/fr active Active
- 2019-09-13 NO NO2019035C patent/NO2019035I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR048652A1 (es) | 4-fenilamino-quinazolin-6-il-amidas | |
| CY1121699T1 (el) | Ενωσεις τριαζινης ως αναστολεις κινασης ρ13 και mtor | |
| PE20090276A1 (es) | Compuestos derivados de imidazoquinolina como moduladores de tlr7 | |
| PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
| PE20091621A1 (es) | Derivados de amina como moduladores de la actividad de tlr y composiciones que los contienen | |
| PE20081679A1 (es) | Compuestos del inhibidor de fosfoinositida 3-cinasa y metodos de uso | |
| PE20060497A1 (es) | Aminas policiclicas sustituidas con arilo como antagonistas de mch | |
| PE20030226A1 (es) | Compuestos arilicos sustituidos con quinuclidinas para el tratamiento de enfermedades | |
| PE20091236A1 (es) | Derivados de pirimidina como immunomoduladores de tlr7 | |
| PE20090733A1 (es) | Derivados de pirazina como bloqueadores de los canales de sodio epitelial | |
| PE20090952A1 (es) | Compuestos de pirazol moduladores de raf | |
| PE20121010A1 (es) | Derivados de bencimidazol | |
| PE20130325A1 (es) | Derivados de piperidina, piperazina o tetrahidropiridilo como antagonistas de trpv1 | |
| PE20071254A1 (es) | Derivados de sulfonamidas como agentes moduladores de los receptores de orexina y su preparacion | |
| PE20091090A1 (es) | Derivados de piperidina como agonistas de receptores muscarinicos | |
| HRP20050933A2 (en) | Organic compounds | |
| HRP20090264T1 (en) | Phenyl-piperazin methanone derivatives | |
| JO2652B1 (en) | Compounds 5,4,2,1 Tetra Hydro-H3-benzazepine Method of preparation and pharmaceutical compounds containing | |
| AR066531A1 (es) | Dihidroquinonas y dihidronaftiridinas como inhibidores de las jnk, composicion farmaceutica | |
| PE20091433A1 (es) | Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procedimientos para su preparacion 177 | |
| CO5631442A2 (es) | Nuevos derivados de indolizina 1,2,3 sustituida, inhibidores de los fgfs, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
| PE20081703A1 (es) | Nuevos derivados triciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| CO6160324A2 (es) | Heterociclos sustituidos que contienen nitrogeno como inhibidores del receptor adp plaquetario | |
| ATE476431T1 (de) | Piperidin- und azetidinderivate als glyt1- inhibitoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |